A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study

Abbott

Status and phase: Terminated; Phase 2

Conditions: Alzheimer's Disease

Treatments: Drug: ABT-089

Study type: Interventional

Funder types: Industry

Identifiers

NCT00809510

M10-745

Details and patient eligibility

About

The purpose of this study is to evaluate the long-term safety and tolerability of ABT-089 in adults with mild-to-moderate Alzheimer's disease.

Enrollment: 63 patients

Sex: All

Ages: 55 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• The subject was randomized into Study M06-876 and completed the study.
• The subject must remain on the same dose of AChEI that was used during the M06-876 study.
• The subject is in general good health, as judged by the investigator

Exclusion criteria

• The subject is currently, or plans to participate in another experimental study during the course of this trial.
• The subject anticipates a move outside the geographic area of the investigative site or is planning extended travel inconsistent with the recommended visit intervals.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

63 participants in 1 patient group

1

Experimental group

Treatment:

Drug: ABT-089